NTLA
Price
$8.50
Change
+$0.43 (+5.33%)
Updated
May 16 closing price
Capitalization
880.46M
74 days until earnings call
PRME
Price
$1.59
Change
+$0.33 (+26.19%)
Updated
May 16 closing price
Capitalization
208.76M
79 days until earnings call
Ad is loading...

NTLA vs PRME

Header iconNTLA vs PRME Comparison
Open Charts NTLA vs PRMEBanner chart's image
Intellia Therapeutics
Price$8.50
Change+$0.43 (+5.33%)
Volume$2.46M
Capitalization880.46M
Prime Medicine
Price$1.59
Change+$0.33 (+26.19%)
Volume$3.24M
Capitalization208.76M
NTLA vs PRME Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. PRME commentary
May 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
May 19, 2025
Stock price -- (NTLA: $8.50 vs. PRME: $1.59)
Brand notoriety: NTLA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 72% vs. PRME: 208%
Market capitalization -- NTLA: $880.46M vs. PRME: $208.76M
NTLA [@Biotechnology] is valued at $880.46M. PRME’s [@Biotechnology] market capitalization is $208.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $289.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 6 bullish, 4 bearish.
  • PRME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PRME.

Price Growth

NTLA (@Biotechnology) experienced а +4.68% price change this week, while PRME (@Biotechnology) price change was +22.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.87%. For the same industry, the average monthly price growth was +9.01%, and the average quarterly price growth was -4.62%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.87% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($880M) has a higher market cap than PRME($209M). NTLA YTD gains are higher at: -27.101 vs. PRME (-45.548). PRME has higher annual earnings (EBITDA): -196.34M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. PRME (190M). PRME has less debt than NTLA: PRME (40.8M) vs NTLA (210M). NTLA has higher revenues than PRME: NTLA (57.9M) vs PRME (2.98M).
NTLAPRMENTLA / PRME
Capitalization880M209M421%
EBITDA-523.98M-196.34M267%
Gain YTD-27.101-45.54860%
P/E RatioN/AN/A-
Revenue57.9M2.98M1,941%
Total Cash602M190M317%
Total Debt210M40.8M515%
FUNDAMENTALS RATINGS
NTLA vs PRME: Fundamental Ratings
NTLA
PRME
OUTLOOK RATING
1..100
979
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as PRME (42) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as PRME (64) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRME
RSI
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 5 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
81%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA349.987.16
+2.09%
Tesla
SPY594.203.74
+0.63%
SPDR® S&P 500® ETF
AAPL211.26-0.19
-0.09%
Apple
BTC.X103191.086000-298.203120
-0.29%
Bitcoin cryptocurrency
GME28.45-0.18
-0.63%
GameStop Corp

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+5.26%
CRSP - NTLA
68%
Closely correlated
+6.77%
BEAM - NTLA
66%
Loosely correlated
+3.71%
RXRX - NTLA
61%
Loosely correlated
+7.29%
RCKT - NTLA
59%
Loosely correlated
-3.35%
DNLI - NTLA
57%
Loosely correlated
-2.68%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+26.19%
CRSP - PRME
62%
Loosely correlated
+6.77%
RXRX - PRME
58%
Loosely correlated
+7.29%
BEAM - PRME
57%
Loosely correlated
+3.71%
NTLA - PRME
54%
Loosely correlated
+5.26%
ALLO - PRME
52%
Loosely correlated
+1.83%
More